News
BIOSYNEX SA: Extension of the distribution agreement between Credo Diagnostics Biomedical Pte Ltd and BIOSYNEX S.A.
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
MD Medical Group Investments Plc: MD Medical Group opens new Medical centre in Moscow Region
Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
Puma Biotechnology to Present at B. Riley Securities’ 3rd Annual Oncology Conference
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of
Simulations Plus Releases DILIsym X (DSX) Beta with Redesigned Software Infrastructure
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services (DSS)
Charles River Establishes eXpDNA™ Plasmid Manufacturing Platform to Expedite DNA Programs
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its eXpDNA™ plasmid platform, established from the Company’s contract development and manufacturing (CDMO)
The Vanguard Group, Inc.: Mediclinic International plc
CLASS ACTION ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Has Filed A Securities Fraud Class Action Lawsuit Against Twist Bioscience Corporation
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities class action lawsuit against Twist Bioscience Corporation (“Twist”) (NASDAQ: TWST) on
Simulations Plus Executes $20 Million Accelerated Share Repurchase Agreement
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced it has entered into an accelerated
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on January 10, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
Guerbet: Intrasense opens its share capital to the Guerbet Group, which announces its intent to file a voluntary tender offer under the same price conditions
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Evolva delivers strong results with 57% revenue growth and increasing margins
Humana, Feeding America® Partner to Support Mobile Food Pantries
Leading health and wellness company Humana Inc. (NYSE: HUM) is helping to address food insecurity with a $625,000 grant to Feeding America, supporting mobile food pantries in nine states.
This
Valbiotis gibt Roadmap für 2023 bekannt: ein entscheidendes Jahr für die Umsetzung der klinischen, industriellen und kommerziellen Strategie
Aufsichtsrechtliche Meldung:
Valbiotis (FR0013254851 – ALVAL, PEA-KMU-qualifiziert), ein kommerziell orientiertes Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlichen
ICON Issues Financial Guidance for Full Year 2023
ICON plc, (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today announced its financial guidance for the year ending December 31, 2023. For the
Inogen Achieves Regulatory Milestones to Support Current and Future Products
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it has achieved regulatory milestones in the
Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous
Inogen Announces Preliminary Fourth Quarter and Full Year 2022 Revenue Within Company Expectations
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced unaudited preliminary revenue results for the
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
EQS-News: Sernova and Evotec on Track to Initiate Clinical Testing of the First iPSC-Derived Islets in Cell Pouch as a Potential Functional Cure for Type 1 Diabetes
EQS-News: BRAIN Biotech AG: BRAIN Group's Akribion Genomics business will prioritize the development of therapeutic applications within its CRISPR technology platform
EQS-Adhoc: BRAIN Biotech AG: prioritizing development of therapeutic applications of the Akribion Genomics technology platform (genome-editing)
Valbiotis Announces Its Roadmap for 2023: a Pivotal Year in the Execution of Its Clinical, Industrial and Commercial Strategy
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a commercially oriented Research and Development company committed to scientific innovation for preventing and combating